Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

CHICAGO -- Progression-free survival (PFS) in metastatic hormone receptor (HR)-positive breast cancer more than doubled with ...

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast ...

AstraZeneca has presented results for the SERENA-6 trial at the American Society for Medical Oncology (ASMO)'s 2025 ...

Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding ...

A new study, sponsored by AstraZeneca and presented at the American Society of Clinical Oncology (ASCO) annual meeting in ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...